Zhendong Chen

机构：South China Normal University, Anhui Medical University, Panyu District Central Hospital, Second Affiliated Hospital of Anhui Medical University · ORCID：0000-0003-1282-2805

发表论文 60 篇 · 总被引 3139 次 · h-index 18

代表论文

• Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial (2025 · The Lancet Oncology · 被引 61)
• Sulfotransferase SULT2B1 facilitates colon cancer metastasis by promoting SCD1‐mediated lipid metabolism (2024 · Clinical and Translational Medicine · 被引 25)
• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 24)
• A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer. (2023 · Journal of Clinical Oncology · 被引 22)
• A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors. (2023 · Journal of Clinical Oncology · 被引 17)
• Comprehensive Analysis of Prognostic Value and Immune Infiltration of Ficolin Family Members in Hepatocellular Carcinoma (2022 · Frontiers in Genetics · 被引 10)